Bill. Thanks
I'd to on briefly transition. CEO like comment review the I drivers, Before growth the
this scruffy lives work and in Bill First and beyond our over a Bill in Inari person his as Bill's warriors, our leadership, and with a Board. products has years. started growth driven continuing to and me the foremost, to to closely patients, thank eight I ideas. X,XXX to to our we products. I Under by contributions want change friend look been been Inari's When company, forward personally during mentor transition Bill broad-based and and has he to approved no to Today, people increasingly big steadfast startup capabilities him space are company multiple last ambition are beyond. both venous markets, with clot a continues for serve shared to commitment over the with to on an multiple we public venture-backed XX at a large established these and
confident this growth of Lastly, our countless more of I recent have humbled the future be all drivers. am let we next our assume couldn't I now the with impact phase lives about made how patients. me growth. pursue and excited to just share to the role our we and I'd we've opportunity like share more as progress you on of to
growth first organization. expansion sales the driver is Our our of
XXX recall our we committed territories, will entered expansion end in this reasons. You accelerate our July XXXX. least organization the months decision of goal We by annual sales with to just at for of nearly the XXX the six reaching of We to made that first territories year. three the over
the year. traction the First, were we at saw encouraged by start we the of
highly impact have on second in territories producing had a deeper driver smaller Second, our penetration favorable accounts. growth
Third, we the year Notably, of of hire the first this more with also launch especially best-in-class XXXX team. focus this have challenging for complete planned enable will year several new while managed expanded complement management to a XXX we nearly to commercial than performance our half of the professionals sales in and new us with macro revenue professionals organization full sales and set delivering of sales products headwinds. later a navigating
our decisions. commercial progress within with most expertise physician customers. and pleased optimistic about the our never the making first with see to half are even hospital also We're growth execution driver, the the with We patients, year. producing half year Most VTE our despite second the existing of adoption back make we're the and solid a deeper success, clinical in informed skills
establish that is triaged to Our systems processes and are consistently to expert. goal VTE identified ensure and patients
useful effort. As territories smaller I are this for mentioned, especially
Our clinical third our to driver growth upon is base evidence. build of
exciting and We some few news updates a here. have
and presented readmission patient of the These can the analysis was and statistically potential patients Competitors on simply with First, major was hypertension. data from No FLASH any FlowTriever Both Meeting safety is have all broader X%. true. pulmonary the for of This safety patients fragile subgroup less are events, in fragile unprecedented not focused was the Society who The the in Interventional of during sort are yet severe thrombectomy XX-day indistinguishable of of profile mortality the high, XX efficacy These the population no treatment of extremely is and excellent patients. literature. FLASH sometimes FlowTriever this the exceptional. Annual procedures even suggested results sick deliveries. are at and presented the PE the than results Radiology. were morbidity study again adverse less population,
high is PE randomized nicely. for is thrombolytics against comparing Next, trial a controlled catheter-directed the PEERLESS, a intermediate superiority and reminder, PEERLESS trial patients. risk as FlowTriever enrolling
to new the data and we resources to Looking we patients. publication trials. patients VTE Every our our us FLAME on research and standard large establish fall registries, FLASH continue will while clinical PE production new we of as and the complete out guidelines. the season, expect this to the we the massive every In XXX U.S. this well, clinical to both commit not of change to efforts significant dataset the change differentiates cohort later study to investigator-initiated patient and report we new And care year the from CLOUT as believe of summary, competition. goal, RCT, report our further advances survival ahead protocol every XXX report dataset complete which DVT also conference Likewise, expect cut for data. PE late-breaking from
our is portfolio. expand product fourth driver to growth Our
exciting share We have to several developments as well. here
number a it combines market we just full Gen-X easier and use. FlowTriever release deliverable system. device features to entered that our of make First, of This more
our reduced. for case devices, new costless fewer to The faster it's fewer total to market already procedure procedures passes release, our technical and times required and more our is transition for this translate better used outcomes clot Simpler underway. limited procedures and were results with During seamless physicians FlowTriever removed customers technology better while patients. more and per
patients. Some improving in The per routinely used of BOLD of our both procedure is results release, acute market also DVT entry progressing our pricing, Feedback is being economics accounts. sheet well. also removes further now recent in and launches chronic it full procedure, costs been is our the product several excellent ClotTriever excellent. in hospital. are included in Because hundred for it has delivering stock the is now also from and
obtained for release. and clearances products, [indiscernible] two are both balloon-guiding Arctic the limited sheet in FDA new we devices Finally, market recently device,
about address market share target corresponding to and much more excited their are soon. they these unmet devices, needs We the
products All investment a of a R&D of result products a unmet these cadence new of designed build address that direct engine steady is needs. new made to the have to are robust we delivering
You more this later products new expect can year.
open case growth in Europe, fully expansion have saw into last is international managers In be back Our focused year, operating despite markets. will at we driver continuing challenging European sequential to growth the environment. each main increased new general We existing again geographies. now In driving on penetration accounts of of our while installed also the international the half accounts. three our team
the during Pacific Beyond America, growth base. and Canada modest off still in a Asia Europe, we case Latin saw a good albeit quarter
these market are year. the regions during We back towards across additional half launches working of the geographic
international previously, material component mix a noted not in revenue we've be overall our As XXXX. of will
to is making we're treat our to this the and enable strategy drivers. by quarters believe believe good investors growth to designed consistently grow our close together, that many investments to Taken our I'd will restating our to can we us we across for These and and more all ways, well. deliberate has and reflects we make. progress have patients. are We working progress believe and we mission intentional that will served like both In investments made come. continue as many
needs our more our are this enthusiastic patients. our are better ideals markets been the serious growth. patients, are to about committed couldn't I'd to people be To-date, phase and unwavering responsibility nor journey Mitch. our large, big I about the more Our of to has ideas. for things guided by significant patient With an like to we turn over do to same commitment and our next that, our to